Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ocugen Inc. (NASDAQ: OCGN) shares were trading higher Thursday in sympathy with other coronavirus vaccine stocks.  Vaccine stocks are likely moving after Moderna Inc. (NASDAQ: MRNA) reported the vaccine saw 93% efficacy six months after the second dose.

Ocugen Stock Is Creeping Up To This Resistance Level

Today, a couple of key catalysts are driving OCGN stock higher by double digits, as investors speculate on what may be announced tomorrow. The post OCGN Stock: 2 Big Reasons Ocugen Is Gaining Today appeared first on InvestorPlace.

OCGN Stock: 2 Big Reasons Ocugen Is Gaining Today

Los Angeles, California--(Newsfile Corp. - August 5, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 2, 2021 and June 10, 2021, inclusive (the...

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

Home Point Capital

Full Truck Alliance Co Ltd

NEW YORK, NY / ACCESSWIRE / August 5, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OCGN, HMPT and YMM

DraftKings

NEW YORK, NY / ACCESSWIRE / August 4, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OCGN, HMPT and DKNG

Los Angeles, California--(Newsfile Corp. - August 4, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 2, 2021 and June 10, 2021, inclusive (the...

INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

James River Group Holdings

Oatly

NEW YORK, NY / ACCESSWIRE / August 3, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of JRVR, OCGN and OTLY

Ocugen (OCGN) is likely to provide updates related to regulatory progress of its COVID-19 vaccine, Covaxin, in the United States when it reports second-quarter 2021 results.

Ocugen (OCGN) to Report Q2 Earnings: What's in the Cards?

Clover Health Investments

Kandi Technologies Group Inc

MicroStrategy Incorporated

Lordstown Motors

Senseonics Holdings

Workhorse Group

Short-squeeze stocks are as popular as ever among retail investors. This list contains some of the high-short-interest names you may not have heard of before.

7 Short-Squeeze Stocks with High Short Interest to Watch

Los Angeles, California--(Newsfile Corp. - August 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 2, 2021 and June 10, 2021, inclusive (the...

INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

TAL Education Group

Even if you aren't risk-averse, you should think long and hard about holding these stocks.

2 Ultra-Risky Stocks I Wouldn't Buy With Free Money

CorMedix

Didi Global

NEW YORK, NY / ACCESSWIRE / August 3, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OCGN, DIDI and CRMD

NEW YORK--(BUSINESS WIRE)---- $OCGN--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of those who acquired Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN) securities from February 2, 2021 through June 10, 2021, inclusive (the “Class Period”). Investors have until August 16, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Ocugen is a biopharmaceutical

INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Ocugen, Inc. (OCGN) Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021, inclusive (the “Class Period”), of the important August 17, 2021 lead plaintiff deadline. SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – OCGN

Barring the slim chance it gets EUA in Canada, which admittedly could result in an outsized move higher? Expect OCGN stock to continue trending lower, eventually falling back to around 70 cents per share.

Throw in The Towel, Ocugen Stock is Not Coming Back

NEW YORK, NY / ACCESSWIRE / August 2, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OCGN, HMPT and DIDI

Los Angeles, California--(Newsfile Corp. - August 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 2, 2021 and June 10, 2021, inclusive (the...

INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

Arcturus Therapeutics

Inovio Pharmaceuticals

Moderna

Novavax

Vaxart

These players delivered triple- and quadruple-digit gains.

Can Last Year's Biggest Vaccine Stocks Crush the Market Again?

Stable Road Acquisition Corp

NEW YORK, NY / ACCESSWIRE / August 1, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

CLASS ACTION UPDATE for SRAC, OCGN and CRMD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

New York, New York--(Newsfile Corp. - July 31, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021, inclusive (the "Class Period"), of the important August 17, 2021 lead plaintiff deadline.SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

Rosen, Top Ranked Investor Counsel, Encourages Ocugen, Inc. Investors with Losses to Secure Counsel Before Important August 17 Deadline in Securities Class Action - OCGN

Ocugen (OCGN) closed at $6.71 in the latest trading session, marking a -1.61% move from the prior day.

Ocugen (OCGN) Dips More Than Broader Markets: What You Should Know

BlueCity Holdings Limited

Frequency Therapeutics

NEW YORK, NY / ACCESSWIRE / July 30, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, OCGN and BLCT

MALVERN, Pa., July 30, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its second quarter 2021 financial results and provide a business update at 8:30 a.m. ET on Friday, August 6, 2021.

Ocugen to Host Conference Call on Friday, August 6 at 8:30 a.m. ET to Discuss Second Quarter 2021 Financial Results and Provide Business Update

NEW YORK, NY / ACCESSWIRE / July 29, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OCGN, HMPT and YMM

While OCGN stock seems like a reasonable speculation based on the worsening Covid-19 crisis, it's still a tough gamble. The post Is Ocugen Worth a Shot Because of the Worsening Pandemic?

News for Ocugen, Inc. Stock (OCGN)